ANI Pharmaceuticals shares climbed 7% over the past week following the company’s forecast of more than $1.0 billion in revenue for fiscal 2026, reflecting 26% growth over 2025. Management highlighted that the rare disease franchise will represent roughly 60% of total sales next year, driven primarily by the continued rollout of purified Cortrophin Gel. The announcement generated renewed investor confidence in ANIP’s ability to sustain high growth and defend its leadership position in niche therapeutic categories.

At the 44th Annual J.P. Morgan Healthcare Conference, CEO Nikhil Lalwani outlined plans to accelerate ANI’s transformation into a leading rare disease company. The purified Cortrophin Gel franchise is projected to generate $540 million to $575 million in revenue in 2026, supported by a 90-person commercial expansion and the initiation of a pivotal Phase 4 clinical trial. This growth will leverage the company’s U.S. manufacturing capabilities and robust R&D platform, enabling multiyear durability and pricing power in orphan indications.

ANI closed 2025 with robust cash flows from its generics segment and exited the year with $285 million in cash and equivalents. The company expects no cash burn in 2026 as high-margin generics EBITDA will continue to fund rare disease investments. Analysts note that ANIP trades at 11.2 times forward earnings, a 43% discount to the broader specialty pharma peer group, underscoring a compelling risk/reward profile for investors seeking exposure to high-growth orphan drugs supported by a stable cash-generating base.